At the end of Q1 2026, 28 institutions reported holding Traws Pharma Inc. (TRAW) in their 13F filings, up 6 from Q4 2025. 11 opened new positions and 7 sold out. The largest holders were Adage Capital Partners Gp, L.L.C. ($1.3M), Ikarian Capital, LLC ($1.2M) and Orbimed Advisors LLC ($1.1M).
Company
Traws Pharma Inc.
CUSIP
68232V884
Latest filing quarter
Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
Institutions
Total Value
New Positions
11
$956K
Exits
7
$148K
All 13F filers, Q4 2025 → Q1 2026: 537,679 shares bought and 336,470 shares sold, net +201,209 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.